Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$148.85

5.27 (3.67%)

, ARIA

Acquired by TKPYY 2/17

$23.75

10.01 (72.85%)

08:11
01/10/17
01/10
08:11
01/10/17
08:11

ARIAD acquisition supports potential takeout premium for TESARO, says Leerink

Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TSRO

Tesaro

$148.85

5.27 (3.67%)

ARIA

Acquired by TKPYY 2/17

$23.75

10.01 (72.85%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$21.72

0.33 (1.54%)

  • 11

    Jan

  • 11

    Jan

  • 11

    Jan

  • 21

    Feb

  • 29

    Apr

  • 30

    Jun

TSRO Tesaro
$148.85

5.27 (3.67%)

12/21/16
JANY
12/21/16
NO CHANGE
Target $44
JANY
Neutral
Clovis price target raised to $44 from $38 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay raised his price target for Clovis Oncology to $44 to reflect his assumption of $36M in Rubraca sales for FY17. Clovis is launching Rubraca in the U.S. with around 85 sales reps, and the analyst assumes a similar sized organization in the major European markets. He assumes Clovis launches the drug without a partner in Europe. He believes the FDA's position on competitor TESARO's (TSRO) niraparib will have implications for Clovis prior to the ARIEL3 data. Chattopadhyay keeps a Neutral rating on Clovis. The stock is up 8% to $45.86 in midday trading.
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
12/27/16
12/27/16
NO CHANGE
Target $151

Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
ARIA Acquired by TKPYY 2/17
$23.75

10.01 (72.85%)

12/01/16
WBLR
12/01/16
NO CHANGE
WBLR
Celgene, Zoetis among top healthcare picks at William Blair
William Blair analysts named their top health care picks for 2017, identifying Evolent Health (EVH) as their top HC Services and HC IT pick, Zoetis (ZTS) as their top dental and animal health pick,and Pacific Biosciences (PACB) as their top diagnostic services and life sciences choice, The firm identified ARIAD (ARIA), Celgene (CELG) and SAGE Therapeutics (SAGE) as their top biotech choices. It named Edwards Lifesciences (EW), Nevro (NVRO), and K2M Group (KTWO) as its favorite med tech picks.
11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.
01/10/17
LEHM
01/10/17
UPGRADE
Target $24
LEHM
Equal Weight
ARIAD upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Paul Choi upgraded ARIAD Pharmaceuticals to Equal Weight saying the all cash acquisition by Takeda is a positive outcome for shareholders. The analyst assumes the deal closes with no competing bids and upped his price target for the shares to $24 from $9.
01/10/17
JEFF
01/10/17
DOWNGRADE
Target $24
JEFF
Hold
ARIAD downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded ARIAD Pharmaceuticals to Hold on expectations the Takeda acquisition will close by the end of February. The analyst views the deal as a "nice surprise at a significant premium." She raised her price target for the shares to $24 from $11.
TKPYY Takeda Pharmaceutical Co. Ltd.
$21.72

0.33 (1.54%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.

TODAY'S FREE FLY STORIES

ALRM

Alarm.com

$38.27

1.26 (3.40%)

05:00
01/18/18
01/18
05:00
01/18/18
05:00
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SYMC

Symantec

$27.52

-0.35 (-1.26%)

04:58
01/18/18
01/18
04:58
01/18/18
04:58
Downgrade
Symantec rating change  »

Symantec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 26

    Feb

NICE

Nice

$92.63

0.67 (0.73%)

04:56
01/18/18
01/18
04:56
01/18/18
04:56
Upgrade
Nice rating change  »

Nice upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

OKTA

Okta

$26.78

0.43 (1.63%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Okta management to meet with KeyBanc »

Meeting with CEO McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 26

    Feb

SSW

Seaspan

$6.99

-0.13 (-1.83%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Seaspan management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NFLX

Netflix

$217.50

-4.03 (-1.82%)

, AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Wedbush digital media analyst hosts a luncheon meeting »

Digital Media Analyst…

NFLX

Netflix

$217.50

-4.03 (-1.82%)

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

GOOG

Alphabet

$1,131.98

10.22 (0.91%)

GOOGL

Alphabet Class A

$1,139.10

8.4 (0.74%)

FB

Facebook

$177.60

-0.79 (-0.44%)

TWX

Time Warner

$92.17

0.26 (0.28%)

DIS

Disney

$111.97

1.28 (1.16%)

FOXA

21st Century Fox

$37.11

0.82 (2.26%)

ROKU

Roku

$41.54

2.35 (6.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

  • 18

    Mar

MVC

MVC Capital

$10.60

-0.12 (-1.12%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
MVC Capital management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

MNST

Monster Beverage

$67.07

2.51 (3.89%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Monster Beverage to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
RBC Capital telecom services analyst hosts luncheon »

Telecom Services Analyst…

ABM

ABM

$38.73

0.26 (0.68%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
ABM to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MDXG

MiMedx

$14.09

0.15 (1.08%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
MiMedx to hold a conference call »

Chairman & CEO Petit,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

SITE

SiteOne Landscape

$72.27

1.09 (1.53%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
SiteOne Landscape management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Breaking General news story  »

Cleveland Federal Reserve…

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Bernstein European food analyst holds an analyst/industry conference call »

European Food &…

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Deutsche Bank to hold a conference »

CEEMEA Conference is…

KEYW

KEYW

$6.51

0.05 (0.77%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
KEYW management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 21

    Feb

  • 22

    Feb

  • 14

    Jun

DSW

DSW

$21.07

0.44 (2.13%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
DSW management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

DIS

Disney

$111.97

1.28 (1.16%)

, VIA

Viacom

$37.85

0.95 (2.57%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Media Analyst Routh,…

DIS

Disney

$111.97

1.28 (1.16%)

VIA

Viacom

$37.85

0.95 (2.57%)

TWX

Time Warner

$92.17

0.26 (0.28%)

CMCSA

Comcast

$41.68

-0.14 (-0.33%)

SPB

Spectrum Brands

$125.16

-0.07 (-0.06%)

DISH

Dish

$45.45

-2.54 (-5.29%)

NFLX

Netflix

$217.50

-4.03 (-1.82%)

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

  • 18

    Mar

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Housing Starts Permits to be reported at 08:30 »

December Housing Starts…

AEIS

Advanced Energy

$75.01

3.17 (4.41%)

, TREE

LendingTree

$372.75

12.75 (3.54%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Needham to hold a conference »

Needham Growth Conference…

AEIS

Advanced Energy

$75.01

3.17 (4.41%)

TREE

LendingTree

$372.75

12.75 (3.54%)

RMNI

Rimini Street

$8.54

0.14 (1.67%)

IPGP

IPG Photonics

$260.95

0.66 (0.25%)

A

Agilent

$72.06

0.83 (1.17%)

GSIT

GSI Technology

$8.16

-0.01 (-0.12%)

B

Barnes Group

$67.60

0.28 (0.42%)

NATI

National Instruments

$46.07

1.38 (3.09%)

AIRG

Airgain

$9.31

0.06 (0.65%)

CRAY

Cray

ESIO

Electro Scientific

$22.01

1.91 (9.50%)

TYL

Tyler Technologies

$191.28

1.65 (0.87%)

CRAI

CRA International

$47.90

0.63 (1.33%)

LSCC

Lattice Semiconductor

$6.45

0.23 (3.70%)

HLIT

Harmonic

$4.00

0.1 (2.56%)

IOTS

Adesto Technologies

$6.70

0.25 (3.88%)

RESN

Resonant

$6.99

0.2 (2.95%)

VG

Vonage

$10.96

0.21 (1.95%)

VSH

Vishay

$22.10

0.7 (3.27%)

IMI

Intermolecular

$1.46

0.09 (6.57%)

AQ

Aquantia

$11.22

0.55 (5.15%)

AOSL

Alpha & Omega

$17.65

0.25 (1.44%)

WWE

WWE

$32.82

0.93 (2.92%)

CTS

CTS Corporation

$27.15

0.4 (1.50%)

DIOD

Diodes

$29.57

0.53 (1.83%)

FN

Fabrinet

$29.11

0.24 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 16

    Feb

  • 26

    Feb

  • 14

    Mar

  • 29

    Mar

  • 04

    May

  • 14

    Jun

IZEA

Izea

$4.88

-0.58 (-10.62%)

04:55
01/18/18
01/18
04:55
01/18/18
04:55
Conference/Events
Izea to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Breaking General news story  »

Week of 1/12 EIA Natural…

04:55
01/18/18
01/18
04:55
01/18/18
04:55
General news
Breaking General news story  »

Week of 1/14 Bloomberg…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.